Catalent, Inc., a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products, is headquartered in the United States. Founded in 2007, Catalent has rapidly expanded its operations across North America, Europe, and Asia, establishing a strong presence in the pharmaceutical and biotechnology industries. The company is renowned for its innovative services, including drug formulation, clinical supply, and commercial manufacturing, which are designed to enhance product performance and patient experience. Catalent's commitment to quality and efficiency has positioned it as a trusted partner for many of the world's top pharmaceutical companies. With a focus on continuous improvement and cutting-edge technology, Catalent remains at the forefront of the industry, achieving significant milestones in drug delivery and development.
How does Catalent's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Catalent's score of 47 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Catalent, Inc., headquartered in the United States, reported total carbon emissions of approximately 134,100,000 kg CO2e for Scope 1 and 2 combined, with Scope 1 emissions at about 12,400,000 kg CO2e and Scope 2 emissions at approximately 39,600,000 kg CO2e (market-based). The company has set ambitious targets to reduce its carbon footprint, committing to a 42% reduction in absolute Scope 1 and 2 greenhouse gas emissions by fiscal year 2030, using fiscal year 2022 as the baseline. Additionally, Catalent aims to decrease Scope 3 emissions related to fuel- and energy-related activities and employee commuting by 25% within the same timeframe. Furthermore, the company plans for 70% of its suppliers, based on emissions, to establish science-based targets by fiscal year 2028. These commitments align with industry standards and reflect Catalent's dedication to addressing climate change and reducing its environmental impact.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 61,000,000 | - | - | 00,000,000 | 00,000,000 |
| Scope 2 | 144,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | - |
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Catalent has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Catalent's sustainability data and climate commitments